<SEC-DOCUMENT>0001213900-20-036341.txt : 20201112
<SEC-HEADER>0001213900-20-036341.hdr.sgml : 20201112
<ACCEPTANCE-DATETIME>20201112064518
ACCESSION NUMBER:		0001213900-20-036341
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201112
FILED AS OF DATE:		20201112
DATE AS OF CHANGE:		20201112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zhongchao Inc.
		CENTRAL INDEX KEY:			0001785566
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-EDUCATIONAL SERVICES [8200]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39229
		FILM NUMBER:		201303223

	BUSINESS ADDRESS:	
		STREET 1:		841 YAN AN MIDDLE ROAD, JING AN DISTRICT
		STREET 2:		NANXI CREATIVE CENTER, SUITE 218
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200040
		BUSINESS PHONE:		021-32205987

	MAIL ADDRESS:	
		STREET 1:		841 YAN AN MIDDLE ROAD, JING AN DISTRICT
		STREET 2:		NANXI CREATIVE CENTER, SUITE 218
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200040
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea129595-6k_zhongchao.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the month of November 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ZHONGCHAO INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Translation of Registrant's name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Nanxi Creative Center, Suite 218</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>841 Yan&rsquo;an Middle Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Jing&rsquo;An District, Shanghai, China 200040</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Tel: 021-32205987</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(Address of Principal Executive Office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Form 20-F &#9746; Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 12, 2020, Zhongchao
Inc. (the &ldquo;Company&rdquo;) issued a press release announcing that the Company and Takeda Pharmaceutical Company Limited (&ldquo;Takeda&rdquo;)
agreed to expand their current scope of cooperation which now covers five of Takeda&rsquo;s subsidiaries in China including the
new addition of Baishen Biotechnology (Shanghai) Co., Ltd. Pursuant to the amended service agreement by and between the Company
and Takeda, the Company shall continue to serve as Takeda&rsquo;s vendor and partner in China, providing a broad range of services
in medical editing, document collation, and medical training and education to Takeda.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A copy of this press release
is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This report does not constitute
an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws
of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none"><A HREF="ea129595ex99-1_zhongchao.htm">Press release dated November 12, 2020.</A></U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Zhongchao Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Weiguang Yang</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD ROWSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weiguang
        Yang</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief
        Executive Officer</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: November 12, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea129595ex99-1_zhongchao.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="color: Black"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: Black"><IMG SRC="image_001.jpg" ALT=""></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>Zhongchao Inc.
and Takeda Pharmaceutical Expand Scope of Cooperation in China</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">Shanghai, China,
November 12, 2020 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (&ldquo;Zhongchao&rdquo; or the &ldquo;Company&rdquo;), a healthcare
services company offering patient management, online healthcare information, professional training and educational services, today
announced that the Company and Takeda Pharmaceutical Company Limited (&ldquo;Takeda&rdquo;) agreed to expand their current scope
of cooperation which now covers five of Takeda&rsquo;s subsidiaries in China including the new addition of Baishen Biotechnology
(Shanghai) Co., Ltd. Pursuant to the amended service agreement by and between Zhongchao and Takeda, Zhongchao shall continue to
serve as Takeda&rsquo;s vendor and partner in China, providing a broad range of services in medical editing, document collation,
medical training and education, and brand building to Takeda.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="color: Black">Weiguang
Yang, Chairman and Chief Executive Officer of Zhongchao, commented, &ldquo;With over 50,000 employees and over $30 billion in
revenues (for the fiscal year ended March 31, 2020), Takeda is a global biopharmaceutical leader and a Fortune Global 500 company.
We are proud that we have been a vendor and partner in China for various medical training and education and brand building programs
sponsored by Takeda since 2018. Takeda has established itself as a values-based, R&amp;D-driven biopharma with strong presence
in the Chinese market and recently announced that it plans to bring at least fifteen new drugs or indications into the Chinese
market over the next 5 years &ndash; widely regarded as one of the most aggressive expansion plans in China by major pharmaceutical
companies. With the renewal of the contract by Takeda with broadened scope of cooperation, we believe this represents a significant
opportunity for us to further grow our business in years to come.&rdquo;</FONT></P>

<P STYLE="color: #1B2F48; font: italic 10pt Times New Roman, Times, Serif; margin: 2pt 0 0; text-indent: 0in; background-color: white"><FONT STYLE="font-style: normal; color: Black">About
Takeda Pharmaceutical Company Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="color: Black">Takeda
Pharmaceutical Company Limited (TSE:4502/NYSE:TAK)(&ldquo;Takeda&rdquo;) is a global, values-based, R&amp;D-driven biopharmaceutical
leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into
highly-innovative medicines. Takeda focuses its R&amp;D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience,
and Gastroenterology (GI). Takeda also makes targeted R&amp;D investments in Plasma-Derived Therapies and Vaccines. Takeda is
focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier
of new treatment options and leveraging our enhanced collaborative R&amp;D engine and capabilities to create a robust, modality-diverse
pipeline. Takeda is committed to improving quality of life for patients and to working with its partners in health care in approximately
80 countries. More information can be found at https://www.takeda.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="color: Black"><B>About Zhongchao
Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">Incorporated in
2012 with headquarter offices in Shanghai and Beijing, China, Zhongchao Inc. is an online provider of healthcare information,
professional training and educational services to healthcare professionals under its &ldquo;MDMOOC&rdquo; platform (www.mdmooc.org)
and to the public under its &ldquo;Sunshine Health Forums&rdquo; platform (<U>www.ygjkclass.com</U>) in China. The Company also
offers patient management services under its &ldquo;Zhongxun&rdquo; platform (<U>www.zhongxun.online</U>). More information about
the Company can be found at its investor relations website at http://izcmd.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B><I>Safe Harbor
Statement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><I>This press release
contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements
include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and
other statements that are other than statements of historical facts. When the Company uses words such as &ldquo;may, &ldquo;will,
&ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo;
&ldquo;estimate&rdquo; or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.&nbsp;Forward-looking
statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties
and risks including, but not limited to, the following:&nbsp; the Company's goals and strategies; the Company's future business
development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional
training and educational services market in China and the other international markets the Company plans to serve; reputation and
brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions
in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing
and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak,
including its impacts across our business and operations.&nbsp; For these reasons, among others, investors are cautioned not to
place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company&rsquo;s
filings with the SEC, which are available for review at <U>www.sec.gov</U>. The Company undertakes no obligation to publicly revise
these forward<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>looking statements to reflect events or circumstances
that arise after the date hereof. </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>For more information, please contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><I>At the Company:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Pei Xu, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Email: xupei@mdmooc.org</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Phone: +86 21-3220-5987</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><I>Investor Relations:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Sherry Zheng&#9;<BR>
Weitian Group LLC<BR>
Email: shunyu.zheng@weitian-ir.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Phone: +1 718-213-7386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] ,D# 2(  A$! Q$!_\0
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MT9;[W'7ZTZB@!GDQ!&01IM888;1@C&,?E1'$D*!(T5$'0*, 4^B@! JABP4
MGJ<=:8D$4<CR)&BN_+,!@GZU)10!&EO#$C)'$BJ^2RA0 <^M+)%'+$8Y$5T/
;56&13Z* L1/;02! \2,(_N97[OTJ6BB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
